News | October 02, 2024
Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
ALS patients experience neuroinflammation and rapid neurodegeneration
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Subscribe To Our Newsletter & Stay Updated
